Ademi LLP investigates Alpine Immune Sciences' $4.9B acquisition by Vertex Pharmaceuticals for potential fiduciary breaches.
Ademi LLP investigates Alpine Immune Sciences, Inc. for potential breaches of fiduciary duty and other violations of law in its transaction with Vertex. Alpine's stockholders will receive $65 per share or approximately $4.9 billion in cash. Vertex Pharmaceuticals will gain access to Alpine's immune treatments in its biggest acquisition ever, paying $65 a share in cash for Alpine. The deal values each share of Alpine at $65, a 67% premium to its closing price on Tuesday.
April 10, 2024
20 Articles